Clinical Trial Update: FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update announces a Phase 1/Phase 2 study of FOLFOX plus lenvatinib as adjuvant therapy for hepatocellular carcinoma after liver transplantation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• FOLFOX chemotherapy regimen (FOLFOX regimen (folinic acid, 5-fluorouracil, oxaliplatin))
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Liver Cancer, Liver Transplant | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING